Diagnostic systems firm Hologic (HOLX) was up as much as 3% on a bad day for the market Friday after Stifel upgraded it to buy from hold. Analyst Jonathan Block wrote that Hologic is overcoming some of the problems that led its growth to flatten out the last couple of years. “Our diligence leads us to believe that Hologic’s transformation from a broken story to a successful turnaround will continue to evolve into a sustainable multi-year growth
Shares of women’s-health company Hologic (HOLX) gapped up 3% in heavy trading in the stock market Thursday after activist investor Carl Icahn bought a large position in the firm. Late Wednesday, Icahn’s company reported that it owned 30.6 million Hologic shares, or 11% of all shares outstanding. “The Reporting Persons acquired their positions in the Shares in the belief that they were undervalued,” stated the Schedule 13D filing with the
Women’s health company Hologic (HOLX) was hit by a series of downgrades Tuesday morning after its quarterly revenue and guidance missed estimates, sending shares down 14% to below 20 in the stock market, a four-month low. Late Monday, Hologic reported sales for its fiscal Q4 ended Sept. 28 of $622.1 million, up 6% from the year-earlier quarter but about $2 million short of analysts’ consensus. Profit rose 5% to 39 cents a share, beating views by 2